FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2513-2514 June 5, 2008 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Brock, M. V. PubMed Citation

To the Editor: Brock et al. (March 13 issue)¹ report that gene methylation, especially methylation of the p16 and CDH13 genes, was associated with early recurrence of stage I non–small-cell lung cancer (NSCLC). We previously evaluated the relationship between methylation of five genes and prognosis in 351 Japanese patients who underwent resection for NSCLC and found that only p16 methylation was significantly related to a poor prognosis.² We analyzed our results again and found that methylation of both p16 and CDH13 was also associated with a poor prognosis in 199 patients with lung adenocarcinomas, even when these tumors were limited . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.